About Curia
Curia is a Healthcare company based in Grafton (United States) founded in 1998, and was acquired by Curia in March 2014. Specialized CDMO services for complex small molecule APIs are offered. It operates on a Professional Services and Managed Services model. Curia has raised $10.5 million across 2 funding rounds from investors including Curia and Sanders Morris. Curia offers products and services including Small Molecule Services, Generic APIs, Biologics Services, and Sterile Drug Product. Its focus areas include Pharmaceuticals and Contract Development and Manufacturing. Its legal entity is Curia Global, Inc.
Company details
Curia is involved in providing comprehensive services for drug discovery, development, and manufacturing across small molecules, generic APIs, and biologics. The company operates in the healthcare sector, focusing on pharmaceutical and biopharmaceutical solutions. Services are offered through a global network of facilities in North America, Europe, and India, ensuring scalability and flexibility. Advanced technologies and scientific expertise are utilized to accelerate drug delivery to patients. Collaboration and tailored solutions are emphasized to meet client needs while maintaining high standards of quality and integrity.
- Headquarters Grafton, United States
- Stage Acquired
- SectorsHealthcare
- Website cedarburghauser.com
- Social LinkedIn X Facebook
- Acquired by Curia (Mar 2014)
- Legal Name Curia Global, Inc.
Products & Services of Curia
Curia offers a comprehensive portfolio of products and services, including Small Molecule Services, Generic APIs, Biologics Services, and Sterile Drug Product.
Services for small molecule drug discovery are provided.
Generic API manufacturing and catalog services are offered.
Biologics discovery and manufacturing solutions are delivered.
Sterile drug product development services are provided.
Funding Insights of Curia
Curia has successfully raised a total of $10.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in February 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.5M
- Total Rounds 2
- Last Round Series A — $3.5M
- First Round $7M
(Mar 2004)
- Investors Count 1
All 2 funding rounds of Curia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2007 | $3.5M | Series A | – | – | |
| Mar 2004 | $7M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Curia
Curia has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Curia and Sanders Morris.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Financial services are provided by Sanders Morris LLC. | 1987 | smhgroup.com | Houston, United States | |
Drug research, development, testing, and consulting services are provided. | 1991 | curiaglobal.com | Albany, United States |
Investor details for Curia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Curia
4 dated milestones of Curia across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Curia is founded.
- Funding First funding round of $7.0M.
- Funding Latest funding round, Series A, of $3.5M.
- Exit Acquired by Curia.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Curia (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curia
Complete news archive for Curia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curia
Curia was founded in 1998 and raised its 1st funding round 6 years after it was founded.
Curia is headquartered in Grafton, United States.
Curia is a funded company, having raised a total of $10.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Mar 2004.
Curia is involved in providing comprehensive services for drug discovery, development, and manufacturing across small molecules, generic APIs, and biologics. The company operates in the healthcare sector, focusing on pharmaceutical and biopharmaceutical solutions. Services are offered through a global network of facilities in North America, Europe, and India, ensuring scalability and flexibility. Advanced technologies and scientific expertise are utilized to accelerate drug delivery to patients. Collaboration and tailored solutions are emphasized to meet client needs while maintaining high standards of quality and integrity.
Curia offers Small Molecule Services, Generic APIs, Biologics Services, and Sterile Drug Product.
Curia has 2 investors. Key investors include Curia, and Sanders Morris.
Curia operates through Curia Global, Inc..
Yes. Curia was acquired by Curia in March 2014.